Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 13,791 matching trials from the live ClinicalTrials.gov search.

Filters: Dallas, Texas Clear all

Conditions: Depression, End Stage Renal Disease
Interventions: Engagement Interview, Cognitive Behavioral Therapy, Antidepressant Drug Therapy; Behavioral · Drug
Lead sponsor: University of Washington; Other
Eligibility: 21 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 3
States / cities: Albuquerque, New Mexico • Dallas, Texas • Seattle, Washington

Conditions: Malnutrition, Sarcopenia
Interventions: medical food with AN777, oral nutritional formula; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 65 Years to 90 Years
Enrollment: 331 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Birmington, Alabama • Santa Rosa, California • Addison, Illinois + 5 more

Conditions: Cancer
Interventions: Lapatinib, Trastuzumab; Drug · Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 112
States / cities: Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 93 more

Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Cerebral Anaplastic Astrocytoma, Childhood Cerebral Astrocytoma, Childhood Choroid Plexus Neoplasm, Childhood Craniopharyngioma, Childhood Grade I Meningioma, Childhood Grade II Meningioma, Childhood Grade III Meningioma, Childhood Infratentorial Ependymoma, Childhood Oligodendroglioma, Childhood Supratentorial Ependymoma, Ependymoma, Newly Diagnosed Childhood Ependymoma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified, Recurrent Childhood Visual Pathway Glioma
Interventions: Cytology Specimen Collection Procedure; Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 18 Years
Enrollment: 1,258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 163
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 123 more

Conditions: Rheumatoid Arthritis
Interventions: AMP-110, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Anniston, Alabama • Orlando, Florida • Palm Harbor, Florida + 4 more

Conditions: Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Interventions: Adavosertib, Paclitaxel, Carboplatin, Gemcitabine, PLD; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years · Female only
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 18
States / cities: Gilbert, Arizona • Tucson, Arizona • La Jolla, California + 14 more

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
Interventions: Bimekizumab; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 1,353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 48
States / cities: Glendale, Arizona • Phoenix, Arizona • Bakersfield, California + 43 more

Conditions: Wrinkle
Interventions: MCD; Device
Lead sponsor: Cytrellis Biosystems, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Sacramento, California • Greenwood Village, Colorado • Miami, Florida + 3 more

Conditions: Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Biliary Tract Cancer
Interventions: Ligufalimab, Cadonilimab; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Apnea, Sleep Disorders, Overweight and/or Obesity
Interventions: Berobenatide, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 8
States / cities: Cullman, Alabama • Little Rock, Arkansas • Riverside, California + 5 more

Conditions: Breast Cancer
Interventions: Nivolumab, Ipilimumab, Nab-paclitaxel; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Los Angeles, California • Sacramento, California • Aurora, Colorado + 5 more

Conditions: Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
Interventions: R932333, Placebo; Drug
Lead sponsor: Rigel Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 12
States / cities: Los Angeles, California • Redwood City, California • South Bend, Indiana + 9 more

Conditions: Colorectal Cancer
Interventions: Fruquintinib; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 44
States / cities: Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 34 more

Conditions: Heart Failure
Interventions: Ziltivekimab, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 4,874 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 172
States / cities: Alexander City, Alabama • Fairhope, Alabama • Huntsville, Alabama + 141 more

Conditions: Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome, Cardiovascular Disease
Interventions: RVX000222, Placebo; Drug
Lead sponsor: Resverlogix Corp; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: linagliptin, glimepiride, linagliptin placebo, glimepiride placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 6,103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 177
States / cities: Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 139 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 43
States / cities: Andalusia, Alabama • Anniston, Alabama • Glendale, Arizona + 38 more

Conditions: Vulvovaginal Candidiasis
Interventions: NDV-3A, NDV-3, Placebo; Biological
Lead sponsor: NovaDigm Therapeutics, Inc.; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 20
States / cities: Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 17 more

Conditions: Migraine
Interventions: EVO756, Dose 1, EVO756, Dose 2, Placebo; Drug
Lead sponsor: Evommune, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 37
States / cities: Chandler, Arizona • Buena Park, California • Fresno, California + 31 more

Conditions: Blunt Trauma, Penetrating Wound, Hemorrhagic Shock
Interventions: 0.9% Sodium Chloride 250 mL bolus, 0.9% Sodium Chloride 2000 mL bolus; Drug
Lead sponsor: University of Washington; Other
Eligibility: 15 Years and older
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 5
States / cities: Birmingham, Alabama • Portland, Oregon • Pittsburgh, Pennsylvania + 2 more

Conditions: Prostate Cancer, Prostate Cancer Patients With Detectable PSA Following Prostatectomy, Prostate Cancer Recurrent, Prostate Cancer Patients Who Have Brachytherapy Seed Implant, Prostate Cancer Patients Treated by Radiotherapy, Cryotherapy
Interventions: 64Cu-SAR-bisPSMA; Drug
Lead sponsor: Clarity Pharmaceuticals Ltd; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 18
States / cities: Irvine, California • Los Angeles, California • Montebello, California + 15 more

Conditions: Chronic Heart Failure
Interventions: HeartWare® VAS (HVAD), Control LVAD; Device
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 47
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more

Conditions: Myasthenia Gravis
Interventions: thymectomy plus prednisone, prednisone alone; Procedure · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 65 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2015
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 29 more

Conditions: Ulcerative Colitis
Interventions: RPC1063; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 877 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 10
States / cities: Tucson, Arizona • Anaheim, California • Mission Hills, California + 7 more

Search by objective public record fields.

A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}

Evaluation of an Oral Nutritional Supplement Containing AN777

Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Study to Evaluate the Safety and Efficacy of the Cytrellis Micro-Coring Device for the Treatment of Moderate to Severe Facial Wrinkles

Ligufalimab and Cadonilimab in Advanced Liver Cancers

A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)

A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread

Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions

A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients With Type 2 Diabetes

Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus

Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis

Study of EVO756 in Adults With Migraine

Field Trial of Hypotensive Versus Standard Resuscitation for Hemorrhagic Shock After Trauma

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

A Clinical Trial to Evaluate the HeartWare™ Ventricular Assist System (ENDURANCE SUPPLEMENTAL TRIAL)

Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis